Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Abbott reports new safety data for Xience V stent

Abbott reports new safety data for Xience V stent

27th May 2010

Abbott has published new clinical data which supports the safety of Xience V, its everolimus-eluting coronary stent system.

The healthcare firm has reported results from two new trials, one of which demonstrated the superiority of Xience V in terms of in-stent late loss to the alternative Taxus Liberte paclitaxel-eluting coronary stent.

In addition, the device was also shown to reduce the likelihood of preventing health issues such as stent thrombosis and cardiac death.

This performance in prevention of stent thrombosis was reinforced by the second trial, which was conducted over the course of a year and involved more than 5,000 patients.

Dr James Hermiller, director of cardiovascular interventions of St Vincent Hospital in Indianapolis and principal investigator of the latter trial, said the results “confirm that the stent thrombosis results seen with Xience V in earlier randomised clinical trials are consistent in real-world clinical practice”.

Earlier this month, Abbott was named as one of Europe’s top employers by the Great Place to Work Institute Europe due to the training and flexible conditions it offers to staff.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.